Otomycosis with Tympanic Membrane Perforation: Treatment Using Clotrimazole Soaked Gelfoam
DOI:
https://doi.org/10.47210/bjohns.2025.v33i2.242Keywords:
Otomycosis, perforated tympanic membrane, medicated gelfoamAbstract
Introduction:
Otomycosis with a perforated tympanic membrane is commonly encountered in clinical practice and can pose a challenge to treat since commonly used clotrimazole ear drops can irritate the middle ear cavity. Here, the objective of the study was to use self-absorbing material like gelfoam soaked in antifungal cream as a patch over the tympanic membrane perforation to reduce seepage of clotrimazole solution into the middle ear and patient's compliance was studied.
Materials and Methods:
26 patients presenting to the out-patient department with otomycosis and a perforated ear drum underwent thorough aural toileting followed by placing multiple pieces of gelfoam soaked in clotrimazole cream to patch the perforation. Patients were then asked to continue clotrimazole ear drops for 2 weeks and were followed up. Compliance to treatment in the form of pain tolerance and response to therapy were noted down.
Results:
44% of patients complained of pain of which 28% experienced mild and 11% experienced moderate pain at the beginning of therapy. 13 out of 26 experienced mild pain on continuing therapy and all but one were compliant with the entire treatment. 73% of patients had complete resolution at the end of 2 weeks and the remaining 6 out of 26 needed additional week of ear drops for complete resolution. 3 of them with a pinpoint perforation had a healed membrane at the end of the therapy.
Conclusion:
Using Clotrimazole-soaked gelfoam pieces may be a safer and more effective alternative for enhancing treatment compliance, achieving better disease clearance, and reducing the number of follow-up visits.
References
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Bengal Journal of Otolaryngology and Head Neck Surgery

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.